Educational guide
LGD-4033 and Pramipexole Interaction: Synergistic | Peptide Database
Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Compound Profiles
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
Pramipexole
Dopamine Agonist | Prolactin Management Alternative
Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors.
Combined Organ Load
Frequently Asked Questions
Can I take LGD-4033 with Pramipexole?
Yes, LGD-4033 and Pramipexole can generally be taken together. Pramipexole supports hormonal recovery from suppression caused by LGD-4033. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Is LGD-4033 and Pramipexole safe together?
Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.
What are the interactions between LGD-4033 and Pramipexole?
Pramipexole supports hormonal recovery from suppression caused by LGD-4033. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.
How should I time LGD-4033 and Pramipexole?
LGD-4033 has a half-life of ~24-36 hours and Pramipexole has a half-life of ~8 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.